| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fcaed31afee960c63f0d21e133fab13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
1997-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0d4e92c38f375172de259b19c3fa36a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf4b82c37722f04adc099bcf322f9de2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e216c22e0dfca39f42423ff6027880c |
| publicationDate |
1999-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0891191-A1 |
| titleOfInvention |
Anti-tumour agent |
| abstract |
An anti-tumour agent comprises a macromolecular carrier moiety, an active alkylating moiety which is a nitrogen mustard and a stabilising moiety which links the active alkylating moiety with the carrier moiety. The stabilising moiety is an oligopeptide which is capable of being cleaved by a tumour-associated protease and which stabilises the active alkylating moiety by electron withdrawal and/or by inducing formation of aggregates. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106905191-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106905191-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106397102-A |
| priorityDate |
1996-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |